NCT05338723View on ClinicalTrials.gov

Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

September 15, 2023

Study Completion Date

September 15, 2023

Conditions
Chemotherapy-induced CardiotoxicityBreast Cancer
Interventions
DRUG

Rosuvastatin 20mg

20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).

Trial Locations (1)

Unknown

The Department of Clinical Oncology, Tanta University Hospital, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT05338723 - Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients | Biotech Hunter | Biotech Hunter